TMEM Cell Trio Density for Metastatic Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to reliably predict the risk of metastatic disease in breast cancer patients, leading to unnecessary chemotherapy for those at low risk and inadequate treatment for those at high risk, as existing prognostic criteria do not accurately predict systemic hematogenous spread.
Innovation Solution
A method to determine the risk of metastasis by assessing the density of direct appositions between endothelial cells, macrophages, and invasive tumor cells in a tumor sample, using specific agents for CD31, CD68, and Mena to identify the tumor microenvironment of metastasis (TMEM), which correlates with the likelihood of metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current prognostic criteria (histopathological grade, tumor size, angiolymphatic invasion) are used to predict metastatic risk, then treatment decisions can be made based on available data, but the prediction accuracy is insufficient leading to both over-treatment and under-treatment
Solution Approach 1:
The patent segments the tumor microenvironment into distinct cellular components (tumor cells, macrophages, endothelial cells) and evaluates their spatial relationships. By dividing the complex metastatic process into observable cellular interactions, the method achieves more precise prediction of metastatic risk compared to traditional holistic assessment methods.
Solution Approach 2:
The patent introduces the concept of TMEM (tumor microenvironment of metastasis) as an intermediary structure that mediates between tumor cells and blood vessels. This intermediary concept allows for more accurate prediction of hematogenous spread by focusing on the specific cellular interactions that facilitate metastasis, rather than relying on general prognostic criteria.
2Reliability
If adjuvant chemotherapy is administered to 80% of breast cancer patients to decrease metastatic risk, then survival rate increases by 3-10%, but 40% of patients receive unnecessary treatment with associated side effects
Solution Approach 1:
The patent enables preliminary identification of patients at high risk for metastasis through detection of TMEM structures in primary tumor samples. By performing this assessment before treatment decisions, clinicians can pre-identify which patients truly need adjuvant chemotherapy, avoiding unnecessary treatment in low-risk patients while ensuring adequate treatment in high-risk patients.
Solution Approach 2:
The patent provides feedback mechanisms through the development of predictive assays and imaging techniques that allow clinicians to assess metastatic risk and adjust treatment decisions accordingly. This feedback loop enables personalized treatment strategies based on individual patient risk profiles rather than uniform treatment approaches.
3Loss of information
If lymph node metastasis assessment is used to predict distant spread, then some information about metastatic potential is obtained, but the correlation is inconsistent as lymphatic and hematogenous spread mechanisms differ
Solution Approach 1:
The patent extracts and focuses specifically on the hematogenous spread pathway by examining the interaction between tumor cells, macrophages, and endothelial cells at blood vessels. This extraction of the specific metastatic pathway of interest allows for more accurate prediction of distant spread via blood circulation, separate from lymphatic spread assessment.
Data Source
AI summary
Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.